This is highly relevant because, as opposed to previous studies, STARBOARD is using front-line anti-PD-1 immunotherapy for comparison, as opposed to BRAF/MEK inhibitors, which currently are rarely used as first-line therapy for melanoma treatment. The gene discussed is MAP2K7; the disease is melanoma.